ZLAB
Zai Lab Limited NASDAQ Listed Sep 20, 2017$18.18
+1.68%
vs $17.88
Mkt Cap $2.0B
52w Low $15.96
8.8% of range
52w High $41.20
50d MA $19.84
200d MA $21.82
P/E (TTM)
-11.2x
EV/EBITDA
—
P/B
2.8x
Debt/Equity
0.3x
ROE
-24.5%
P/FCF
-12.3x
RSI (14)
55.40
ATR (14)
$0.65
Beta
0.86
50d MA
$19.84
200d MA
$21.82
Avg Volume
946.7K
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Jinchuang Plaza · Shanghai 201210 · CN
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 21.01 | -2.3% | -5.9% | -5.9% | +5.3% | -0.3% | +4.8% | — |
| Feb 26, 2026 | AMC | -0.44 | -0.46 | -4.5% | 19.69 | -3.8% | -2.4% | -4.2% | -3.8% | +8.7% | +0.2% | — |
| Nov 6, 2025 | AMC | -0.28 | -0.33 | -17.9% | 23.15 | -4.3% | -5.4% | -0.0% | +0.5% | -0.5% | -0.7% | — |
| Aug 7, 2025 | AMC | -0.37 | -0.37 | +0.0% | 34.08 | -0.2% | +2.6% | -0.9% | -1.0% | +3.8% | -2.0% | — |
| May 8, 2025 | AMC | -0.50 | -0.45 | +10.0% | 29.14 | +3.3% | +0.3% | +0.5% | -2.7% | -1.7% | +2.2% | — |
| Feb 27, 2025 | AMC | -0.61 | -0.80 | -31.1% | 34.38 | -4.1% | +0.8% | -8.4% | +7.2% | +5.6% | -1.4% | — |
| Nov 12, 2024 | AMC | -0.75 | -0.42 | +44.0% | 28.96 | +3.9% | +3.4% | -11.0% | +1.5% | -7.0% | +3.9% | — |
| Aug 6, 2024 | AMC | -0.66 | -0.82 | -24.2% | 18.11 | +13.2% | -8.1% | +3.6% | -5.7% | +0.1% | -0.1% | — |
| May 8, 2024 | AMC | -0.93 | -0.55 | +40.9% | 16.57 | +21.0% | +26.8% | -4.4% | +7.2% | +0.1% | -3.2% | — |
| Feb 27, 2024 | AMC | -0.87 | -0.98 | -12.6% | 22.49 | -3.1% | -7.5% | +0.9% | +0.6% | -3.2% | -7.4% | — |
| Nov 7, 2023 | AMC | -0.94 | -0.71 | +24.5% | 28.31 | +8.3% | +6.0% | -6.2% | +0.0% | -4.0% | +4.8% | — |
| Aug 7, 2023 | AMC | -0.74 | -1.25 | -68.9% | 26.46 | -4.7% | -8.6% | +9.1% | -2.4% | +0.2% | -0.8% | — |
| Mar 1, 2023 | AMC | -1.04 | -0.65 | +37.5% | 40.38 | -9.2% | -8.5% | +10.8% | -2.6% | -4.2% | -4.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | JP Morgan | Maintains | Overweight → Overweight | — | $19.02 | $18.98 | -0.2% | -1.0% | -1.2% | -2.8% | -2.7% | -0.8% |
| Feb 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $19.69 | $18.95 | -3.8% | -2.4% | -4.2% | -3.8% | +8.7% | +0.2% |
| Feb 5 | JP Morgan | Maintains | Overweight → Overweight | — | $17.00 | $17.34 | +2.0% | -0.1% | +6.0% | +2.4% | +6.0% | -2.7% |
| Aug 11 | Citigroup | Maintains | Buy → Buy | — | $34.96 | $34.72 | -0.7% | -0.9% | -1.0% | +3.8% | -2.0% | +2.3% |
| Jun 30 | Leerink Partners | Maintains | Outperform → Outperform | — | $34.74 | $36.26 | +4.4% | +0.7% | +0.6% | +0.9% | +2.6% | -2.5% |
| Mar 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $33.91 | $35.04 | +3.3% | +6.7% | +3.1% | -3.1% | +3.2% | -2.3% |
| Mar 13 | JP Morgan | Maintains | Overweight → Overweight | — | $35.43 | $35.45 | +0.1% | +2.0% | +5.7% | +0.4% | -1.1% | +0.2% |
| Mar 3 | BofA Securities | Downgrade | Buy → Neutral | — | $34.64 | $33.70 | -2.7% | -8.4% | +7.2% | +5.6% | -1.4% | +2.9% |
| Oct 21 | JP Morgan | Maintains | Overweight → Overweight | — | $27.49 | $27.43 | -0.2% | +1.9% | +2.9% | +0.4% | +14.7% | -2.4% |
| Jul 12 | JP Morgan | Maintains | Overweight → Overweight | — | $17.84 | $18.27 | +2.4% | +1.1% | -0.2% | +3.2% | +0.9% | +0.3% |
| Feb 29 | Citigroup | Maintains | Buy → Buy | — | $20.80 | $21.60 | +3.8% | +0.9% | +0.6% | -3.2% | -7.4% | +4.7% |
| Nov 30 | JP Morgan | Maintains | Overweight → Overweight | — | $27.10 | $27.97 | +3.2% | +0.7% | +0.8% | -1.9% | -0.7% | +2.6% |
| Oct 26 | Goldman Sachs | Maintains | Buy → Buy | — | $24.06 | $23.65 | -1.7% | -4.5% | +2.3% | +8.0% | -0.7% | -1.8% |
| Oct 26 | Citigroup | Maintains | Buy → Buy | — | $24.06 | $23.65 | -1.7% | -4.5% | +2.3% | +8.0% | -0.7% | -1.8% |
| Oct 17 | JP Morgan | Maintains | Overweight → Overweight | — | $25.03 | $25.00 | -0.1% | -0.4% | -1.5% | -4.3% | +1.7% | +0.5% |
| Oct 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $23.85 | $23.88 | +0.1% | -1.0% | +1.6% | +4.1% | -5.6% | +7.0% |
| Sep 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $25.76 | $26.30 | +2.1% | +0.1% | -1.7% | +0.2% | -5.6% | +2.0% |
| Jun 12 | BofA Securities | Maintains | Buy → Buy | — | $28.16 | $28.26 | +0.4% | -1.9% | +0.0% | +0.1% | +2.9% | +2.1% |
| May 11 | Citigroup | Maintains | Buy → Buy | — | $37.51 | $36.86 | -1.7% | -2.2% | -8.5% | +0.2% | +0.1% | -0.6% |
| Mar 16 | JP Morgan | Maintains | Overweight → Overweight | — | $32.00 | $31.58 | -1.3% | +7.1% | -1.2% | -10.8% | +7.6% | -5.7% |
| Nov 18 | JP Morgan | Maintains | Overweight → Overweight | — | $35.53 | $35.00 | -1.5% | -1.6% | -0.2% | -4.3% | -0.0% | -5.0% |
| Nov 11 | Citigroup | Maintains | Buy → Buy | — | $30.39 | $30.69 | +1.0% | +24.3% | -2.1% | +4.8% | -8.6% | +0.4% |
| Aug 9 | Citigroup | Maintains | Buy → Buy | — | $47.08 | $47.50 | +0.9% | -4.0% | -1.1% | +0.6% | -1.8% | +3.6% |
| May 12 | Citigroup | Maintains | Buy → Buy | — | $25.03 | $25.03 | +0.0% | +8.2% | +22.7% | -0.8% | +7.3% | -2.4% |
| May 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $26.24 | $30.00 | +14.3% | -4.6% | +8.2% | +22.7% | -0.8% | +7.3% |
| Apr 21 | SVB Leerink | Maintains | Outperform → Outperform | — | $45.00 | $45.70 | +1.6% | -6.2% | +2.8% | +5.8% | -10.2% | +3.8% |
| Apr 4 | JP Morgan | Maintains | Overweight → Overweight | — | $45.47 | $46.01 | +1.2% | +9.3% | -3.4% | -2.1% | -0.7% | -6.7% |
| Mar 2 | SVB Leerink | Maintains | Outperform → Outperform | — | $52.55 | $50.93 | -3.1% | -0.0% | -20.3% | -3.2% | -8.1% | -1.4% |
| Dec 15 | JP Morgan | Maintains | Overweight → Overweight | — | $62.69 | $59.34 | -5.3% | -12.4% | +20.7% | +10.6% | -7.0% | +1.5% |
| Nov 11 | Citigroup | Maintains | Buy → Buy | — | $87.82 | $87.51 | -0.4% | -3.0% | -0.0% | +0.9% | +5.9% | -0.4% |
| Nov 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $86.69 | $87.62 | +1.1% | +1.3% | -3.0% | -0.0% | +0.9% | +5.9% |
| Oct 12 | Bernstein | Maintains | Market Perform → Perform | — | $101.70 | $100.80 | -0.9% | -2.1% | +2.6% | +0.1% | -0.2% | -2.8% |
| Jun 1 | SVB Leerink | Maintains | Outperform → Outperform | — | $177.66 | $177.91 | +0.1% | +1.3% | -1.8% | -0.3% | -2.7% | -0.1% |
| Apr 14 | SVB Leerink | Maintains | Outperform → Outperform | — | $161.29 | $159.01 | -1.4% | +2.2% | -0.7% | +0.4% | +0.0% | -8.3% |
| Feb 3 | SVB Leerink | Maintains | Outperform → Outperform | — | $176.78 | $174.91 | -1.1% | -1.9% | +2.8% | -0.4% | +3.4% | +0.1% |
| Sep 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $78.50 | $79.01 | +0.6% | -5.7% | +1.6% | +3.0% | +1.8% | +4.8% |
| Dec 30 | Citigroup | Maintains | Buy → Buy | — | $40.25 | $42.00 | +4.3% | +0.4% | +2.9% | +2.5% | -7.0% | -1.4% |
| Sep 4 | China Renaissance | Maintains | Buy → Buy | — | $32.54 | $33.65 | +3.4% | +2.0% | +1.6% | +2.0% | +3.3% | -1.7% |
| Jul 5 | Macquarie | Maintains | Outperform → Outperform | — | $36.33 | $36.54 | +0.6% | -0.1% | -1.2% | +0.1% | +0.5% | -0.8% |
| Jan 29 | Credit Suisse | Maintains | Outperform → Outperform | — | $26.05 | $26.31 | +1.0% | +5.0% | -1.4% | +0.1% | +0.8% | -0.1% |
| Feb 14 | JP Morgan | Maintains | Overweight → Overweight | — | $22.00 | $23.60 | +7.3% | +10.1% | -1.3% | -1.7% | +3.2% | -1.1% |
| Feb 14 | JP Morgan | Upgrade | Neutral → Overweight | — | $22.00 | $23.60 | +7.3% | +10.1% | -1.3% | -1.7% | +3.2% | -1.1% |
| Oct 16 | JP Morgan | Maintains | Neutral → Neutral | — | $32.19 | $31.57 | -1.9% | -0.6% | -3.6% | -7.1% | -3.7% | +2.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | Du Ying | Chairperson & CEO | Sell | 50,000 | $19.00 | $950K | 1,122,626 | +2.40% | +1.30% |
| May 15, 2026 | Du Ying | Chairperson & CEO | Sell | 50,000 | $20.74 | $1.0M | 1,122,626 | +2.40% | +1.30% |
8-K
Zai Lab Limited -- 8-K Filing
Zai Lab shareholders approved the re-election of John D. as a director, affirming continuity in the company's board leadership.
Jun 17
8-K
Zai Lab Limited -- 8-K Filing
Zai Lab reported Q1 2026 results showing progress on its global oncology and immunology pipeline, with multiple ongoing clinical trials advancing the company's development efforts.
May 7
8-K
Zai Lab Limited -- 8-K Filing
Zai Lab reported 2025 fourth-quarter and full-year financial results, demonstrating continued operational progress under CEO Samantha Du's leadership across its NASDAQ and Hong Kong Exchange listings.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rtw Investments, Lp | 6,574,032 | $124M | Reduced | Mar 2026 |
| 2 | Citadel Advisors Llc | 1,688,632 | $32M | — | Mar 2026 |
| 3 | Adar1 Capital Management, Llc | 1,425,367 | $27M | New | Mar 2026 |
| 4 | Fmr Llc | 1,262,391 | $24M | Reduced | Mar 2026 |
| 5 | Morgan Stanley | 579,410 | $10M | Added | Dec 2025 |
| 6 | Ubs Group Ag | 504,191 | $9M | Reduced | Mar 2026 |
| 7 | Schroder Investment Management Group | 393,167 | $7M | Added | Mar 2026 |
| 8 | Jane Street Group, Llc | 382,062 | $7M | New | Dec 2025 |
| 9 | Nan Fung Trinity (Hk) Ltd | 346,466 | $7M | Added | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 309,723 | $6M | Added | Mar 2026 |
| 11 | Superstring Capital Management Lp | 275,818 | $5M | Added | Mar 2026 |
| 12 | Aberdeen Group Plc | 237,739 | $4M | New | Mar 2026 |
| 13 | Walleye Capital Llc | 189,356 | $4M | Reduced | Mar 2026 |
| 14 | Privium Fund Management B.v. | 132,189 | $2M | — | Mar 2026 |
| 15 | Bnp Paribas Asset Management Holding S.a. | 116,560 | $2M | Added | Mar 2026 |
| 16 | Principal Financial Group Inc | 101,782 | $2M | Reduced | Dec 2025 |
| 17 | Hudson Bay Capital Management Lp | 90,000 | $2M | New | Dec 2025 |
| 18 | Barometer Capital Management Inc. | 66,500 | $1M | New | Mar 2026 |
| 19 | Susquehanna International Group, Llp | 65,248 | $1M | Added | Mar 2026 |
| 20 | D.e. Shaw & Co | 63,243 | $1M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.04B
Enterprise Value
$1.28B
P/E (TTM)
-11.18x
Forward P/E
—
PEG Ratio
0.29x
P/B
2.78x
P/S
4.33x
P/FCF
-12.33x
EV/EBITDA
—
Shares Out
109.5M
Financials (TTM)
Revenue
$460.2M
Net Income
-$175.5M
EBITDA
-$158.2M
Free Cash Flow
-$158.9M
Op Cash Flow
-$150.8M
EPS Basic
$-1.60
EPS Diluted
$-1.60
EPS Forward
$-1.88
Gross Margin
58.6%
Op Margin
-49.9%
Net Margin
-38.1%
Balance Sheet
Total Assets
$1.17B
Total Liab.
$456.9M
Total Equity
$715.5M
Cash
$689.6M
LT Debt
$13.4M
Book Value/Sh
$6.53
Debt/Equity
0.31x
Current Ratio
2.45
Quick Ratio
2.27
Returns & Growth
ROE
-24.5%
ROA
-15.0%
ROIC
-23.3%
Rev Growth YoY
+15.3%
EPS Growth YoY
+38.5%
Price Returns
2W
-13.0%
1M
-18.3%
3M
-8.0%
6M
-13.3%
12M
-41.3%
Technicals
52W High
$41.20
52W Low
$15.96
50d MA
$19.84
200d MA
$21.82
RSI (14)
55.40
ATR (14)
$0.65
Beta
0.86
Avg Volume
947K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$35.00
High
$35.00
Low
$35.00
Median
$35.00
Data updated apr 27, 2026 11:46am
· Source: financialmodelingprep.com